ROIV ROIVANT SCIENCES LTD Operational Disruptions 8-K Filing 2023 - Interim Data Announcement Roivant Sciences Ltd. announced interim data from a Phase 2b study of RVT-3101 for the treatment of ulcerative colitis.Get access to all SEC 8-K filings of the ROIVANT SCIENCES LTD